SCHEMBL865294

SCHEMBL865294

O=C(O)C=Cc1ccc(OCc2ccccc2)cc1F

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.61
KDM4E B2RXH2 1/20 0.61
PKM P14618 1/20 0.61
PTGER3 P43115 3/20 0.61
PTGDR Q13258 1/20 0.61
MIF P14174 1/20 0.56
PTGER1 P34995 2/20 0.56
PTGER4 P35408 2/20 0.56
PTGER2 P43116 2/20 0.56
PLA2G2D Q9UNK4 1/20 0.53
BACE1 P56817 3/20 0.50
GSK3B P49841 1/20 0.50
HDAC8 Q9BY41 1/20 0.49
MAOB P27338 1/20 0.49
ALOX5 P09917 1/20 0.49
LTB4R Q15722 1/20 0.48
LTB4R2 Q9NPC1 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2781980 1.00 ALDH1A1 (0.61) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL865293 1.00 ALDH1A1 (0.61) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL865803 0.87 HDAC8 (0.57) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL865802 0.87 HDAC8 (0.57) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL1723809 0.87 HDAC8 (0.57) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL16516226 0.86 ALDH1A1 (0.64) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL16516225 0.86 ALDH1A1 (0.64) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL7909151 0.85 PTGER3 (0.68) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL7191225 0.85 PTGER3 (0.68) ALDH1A1KDM4EPKMPTGER3PTGDR
SCHEMBL16848326 0.84 ALDH1A1 (0.61) ALDH1A1KDM4EPKMPTGER3PTGDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120077793-A1 Compounds for the Treatment of Metabolic Disorders PROSIDION LIMITED (GB) 2012-03-29 US disclosed
US-20100286112-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-11-11 US disclosed
WO-2010103333-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2010-09-16 WO disclosed
EP-2200609-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS Prosidion Limited (GB) 2010-06-30 EP disclosed
WO-2009034388-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS PROSIDION LIMITED (GB) 2009-03-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100286112-A1 COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS GPR119, DPP4, DPP9 ALDH1A1 914/4885KDM4E 2245/4885PKM 1485/4885
US-20120077793-A1 Compounds for the Treatment of Metabolic Disorders GPR119, GPR132, FFAR2 ALDH1A1 1300/4885KDM4E 3483/4885PKM 1490/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.